US Embassy Cracks Down on Indian Executives Over Fentanyl Precursor Trafficking

The US Embassy in New Delhi has taken a firm stand against Indian business figures and their families associated with trafficking fentanyl precursors by revoking and denying their US visas. These decisions, grounded in sections 221(i), 212(a)(2)(C), and 214(b) of the Immigration and Nationality Act, highlight the possibility of ineligibility for US travel for these individuals, according to an official statement released on Thursday.

This decisive move underscores the United States' unwavering commitment to eradicating the illegal drug trade, specifically targeting the perilous synthetic opioid, fentanyl. Consequently, those embroiled in this activity, along with close family members, face potential travel restrictions to the US. The embassy is also marking executives from companies known for fentanyl precursor trafficking for increased scrutiny in future visa applications.

Jorgan Andrews, the US Embassy's Charge d'affaires, reaffirmed the embassy's dedication to tackling illegal drug trafficking, emphasizing that those engaged in the unlawful production and transport of drugs into the United States might face consequences, including denied access. The embassy expressed its appreciation for India's cooperation in addressing this cross-border menace, highlighting the joint mission to safeguard citizens from these illicit substances. The statement also drew attention to the Trump Administration's prior actions against fentanyl trafficking and applauded ongoing bilateral efforts to combat shared challenges.